HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs.

Abstract
A decade after our discovery of the involvement of proprotein convertase subtilisin/kexin type 9 (PCSK9) in cholesterol metabolism through the identification of the first mutations leading to hypercholesterolemia, PCSK9 has become one of the most promising targets in cholesterol and cardiovascular diseases. This challenging work in the genetics of hypercholesterolemia paved the way for a plethora of studies around the world allowing the characterization of PCSK9, its expression, its impact on reducing the abundance of LDL receptor, and the identification of loss-of-function mutations in hypocholesterolemia. We highlight the different steps of this adventure and review the published clinical trials especially those with the anti-PCSK9 antibodies evolocumab (AMG 145) and alirocumab (SAR236553/REGN727), which are in phase III trials. The promising results in lowering LDL cholesterol levels raise hope that the PCSK9 adventure will lead, after the large and long-term ongoing phase III studies evaluating efficacy and safety, to a new anticholesterol pharmacological class.
AuthorsMarianne Abifadel, Sandy Elbitar, Petra El Khoury, Youmna Ghaleb, Mélody Chémaly, Marie-Line Moussalli, Jean-Pierre Rabès, Mathilde Varret, Catherine Boileau
JournalCurrent atherosclerosis reports (Curr Atheroscler Rep) Vol. 16 Issue 9 Pg. 439 (Sep 2014) ISSN: 1534-6242 [Electronic] United States
PMID25052769 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Chemical References
  • Anticholesteremic Agents
  • PCSK9 protein, human
  • Proprotein Convertase 9
  • Proprotein Convertases
  • Serine Endopeptidases
Topics
  • Animals
  • Anticholesteremic Agents (therapeutic use)
  • Genetic Predisposition to Disease
  • Humans
  • Hypercholesterolemia (drug therapy, genetics)
  • Mutation (genetics)
  • Proprotein Convertase 9
  • Proprotein Convertases (genetics)
  • Recovery of Function (genetics)
  • Serine Endopeptidases (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: